Workpackage leaders
|
Workpackage |
Participating partners |
Workpackage leader |
Contact |
|
WP 1: Generation of a high quality in vivo (animal and human)database |
P4, P24, P29, P36 |
Thomas Cole |
|
|
WP 2: Generation of a high quality in vitro database |
P8, P14, P15, P23 |
Dr. Richard Clothier |
University of Nottingham, Nottingham, UK |
|
WP 3: Iteritive amendment of the testing strategy |
P4, P10, P17, P19, P26 |
Dr. Sandra Coecke |
|
|
WP 4: New cell systems and new endpoints |
P9, P11, P14, P21
|
Prof. José-Enrique O´Connor |
|
|
WP 5: Role of adsorption, distribution and elimination |
P5, P6, P13, P15, P27, P34, P35 |
Dr. Bas Blaauboer |
|
|
WP 6 : Role of metabolism |
P3, P7, P15, P23, P31 |
Dr. Maria José Gómez-Lechón |
|
|
WP 7.1: Role target organ toxicity (brain) |
P4, P5, P13, P16, P20, P37 |
Dr. Anna Forsby |
|
|
WP 7.2: Role target organ toxicity (kidney) |
P18, P25 |
Prof. Michael P.Ryan |
|
|
WP 7.3: Role target organ toxicity (liver) |
P3, P9, P12, P15, P18, P28, P31 |
Prof. José Castell |
|
|
WP 8: Technical optimisation of the modified testing strategy |
P1, P2, P3, P4, P5, P6 , P8, P9, P16, P25, P26, P32 |
Dr. Bas Blaauboer |
|
|
WP 9: Prevalidation of the testing strategy |
P2, P3, P4, P5, P6, P8, P9, P16, P25 |
Dr. Pilar Prieto |
|
|
WP 10: Management, dissemination and exploitation of results |
P1, P2, P3, P4, P5, P6, P8, P9, P16, P25, P33 |
Dr. Leila Risteli |